scholarly journals Chinese herbal medicines for mild cognitive impairment: A protocol for meta-analysis and trial sequential analysis

2021 ◽  
Author(s):  
Si-Chun Gu ◽  
◽  
Li-Min Zhang ◽  
Chun-Xu Wang ◽  
Yan-Jie Qu ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Herbal Medicines ◽  
Trial Sequential Analysis ◽  
Chinese Herbal Medicines ◽  
Chinese Herbal

scholarly journals Chinese herbal medicines for mild cognitive impairment

Medicine ◽  
2021 ◽  
Vol 100 (39) ◽  
pp. e27323
Author(s):  
Si-Chun Gu ◽  
Li-Min Zhang ◽  
Chun-Xu Wang ◽  
Yan-Jie Qu ◽  
Jing-Yi Ma ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Herbal Medicines ◽  
Chinese Herbal Medicines ◽  
Chinese Herbal

scholarly journals Does Adjuvant Treatment with Chinese Herbal Medicine to Antidiabetic Agents Have Additional Benefits in Patients with Type 2 Diabetes? A System Review and Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
De Jin ◽  
Jiaxing Tian ◽  
Qi Bao ◽  
Haiyu Zhang ◽  
Qiyou Ding ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Herbal Medicines ◽  
Controlled Trials ◽  
Antidiabetic Agents ◽  
Chinese Herbal Medicines ◽  
Randomized Controlled ◽  
Chinese Herbal

Introduction. In the present meta-analysis, we aimed to determine the effects of adjuvant treatment with Chinese herbal medicine (CHM) on antidiabetic agents having additional benefits in patients with type 2 diabetes. Methods. Randomized controlled trials were identified by searching the Cochrane Library, PUBMED, EMBASE, MEDLINE, the China National Knowledge Internet, Web of Science, Global Health, International Pharmaceutical Abstracts and the China biology medicine, Wanfang, and VIP databases. The intervention group received CHM as add-on treatment to antidiabetic agents therapy, and the control group received placebos in addition to antidiabetic agents or antidiabetic agents alone. We assessed pooled data, including weighted mean differences and 95% confidence intervals (CIs) using a random-effects model. Results. A total of 125 randomized controlled trials were included. 10 articles were included based on literature screening. All trials contrasted Chinese herbal medicines or Chinese herbal medicines + antidiabetic agents with placebo or antidiabetic agents + placebo and included a total of 2004 individuals with T2DM. All selected trials displayed evidence of high methodological quality and possessed a low risk of bias. Meta-analysis of the trials demonstrated that Chinese herbal medicines resulted in a more favorable blood glucose profile in contrast to placebo (P<0.05). The total efficacy rate differed significantly between the two groups (P<0.001). All ten included studies reported the occurrence of tolerable adverse effects. Conclusions. The results showed that in the intervention group, greater reductions were achieved for glucose control and body weight. The combined use of drugs improves the curative effect and has fewer adverse events and has additional benefits in patients with type 2 diabetes. This trial is registered with PROSPERO (CRD42018093867).

Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

2016 ◽  
Vol 30 (10) ◽  
pp. 1592-1604 ◽  
Author(s):  
Lin Dong ◽  
Brian H May ◽  
Mei Feng ◽  
Anna J Hyde ◽  
Hsiewe Ying Tan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Cognitive Outcomes ◽  
Chinese Herbal

scholarly journals Protocol for Chinese Herbal Medicines Decoction Treatment of Angina Pectoris: a Systematic Review With Bayesian Network Meta-analysis

2021 ◽  
Author(s):  
Nan Li ◽  
Wentai Pang ◽  
Fengwen Yang ◽  
Bo Pang ◽  
Xinyao Jin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Angina Pectoris ◽  
Herbal Medicine ◽  
Bayesian Network ◽  
Meta Analysis ◽  
Herbal Medicines ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Chinese Herbal Medicines ◽  
Chinese Herbal

Abstract Background Angina pectoris (AP) is the primary symptom of coronary heart disease. Evidence has shown Chinese herbal medicines can bring benefits to patients suffering from AP. There are many kinds of herbal medicines. However, the difference between them has not been systematically analysed. It is uncertain which one is better. For comparison and ranking, a systematic review and network meta-analysis is needed. Methods We will search for the following 6 electronic databases: China Biological Medicine DataBase(CBM), China National Knowledge Infrastructure(CNKI), WanFang Database, PubMed, Embase and the Cochrane Library, from inception to May 2021. Randomized controlled trials, which aim to assess the efficacy and safety of 5 kinds of Chinese herbal medicine for AP will be included. The outcomes include reduction of AP, improvement of the electrocardiogram and adverse events. The study screening and data extraction will be presented by 2 researchers. The risk of bias will be assessed according to the Cochrane handbook. A Bayesian network meta-analysis will be performed to compare the efficacy of 5 Chinese herbal medicines. Surface under the cumulative rank curve value will be calculated to rank the efficacy of each herbal medicine.DiscussionOur protocol will be expected that the results of this study will provide evidence for Clinical Practice Guideline, clinical decisions, and development of proprietary Chinese medicines.Systematic review registrationPROSPERO registration number: CRD42019146185.

scholarly journals Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

2021 ◽  
Vol 12 ◽  
Author(s):  
Hui Zheng ◽  
Song Jin ◽  
Yin-Li Shen ◽  
Wen-Yan Peng ◽  
Kun Ye ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Herbal Medicine ◽  
Sequential Analysis ◽  
Primary Outcome ◽  
Meta Analysis ◽  
Trial Sequential Analysis ◽  
Controlled Trials ◽  
Chinese Herbal ◽  
Irritable Bowel

Purpose: Chinese herbal medicine (CHM) is an important complementary and alternative therapy for the management of irritable bowel syndrome (IBS). Previous meta-analyses suggested that CHM is effective for IBS; nonetheless, its effectiveness is inconclusive owing to repeated significance testing. We aimed to examine the efficacy and safety of CHM for IBS through a meta-analysis and trial sequential analysis (TSA).Methods: We searched OVID Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from January 1, 1980, to September 20, 2020. The primary outcome was adequate relief of global IBS symptoms. The secondary outcomes included relief of abdominal pain and treatment-related adverse events. The relative ratio (RR) and required information size (RIS) were calculated for each outcome.Results: Ten trials recruiting 2,501 participants were included. Seven (70%) trials were at low risk of bias (RoB). Compared with placebo, CHM was associated with a significantly higher proportion of adequate relief of global IBS symptoms [RR 1.76 (95% confidence interval (95%CI), 1.33–2.33); I2 = 81.1%; p &lt; 0.001]. The RIS was 1,083 for the primary outcome, and the accrued information size was 1,716. The analysis of the relief of abdominal pain (three trials with 916 participants) showed similar results compared with placebo [RR 1.85 (95%CI, 1.59–2.14); I2 = 0%; p &lt; 0.001; RIS = 197 participants]. CHM was associated with a higher proportion of adverse events compared with placebo [RR 1.51 (95%CI, 1.14–2); I2 = 0%; p = 0.004].Conclusion: CHM was effective in relieving IBS symptoms but caused a higher adverse event rate than placebo. TSA analysis confirmed the findings with sufficient information size.

scholarly journals Reporting quality of Cochrane systematic reviews with Chinese herbal medicines

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Xuan Zhang ◽  
Qi-Ying Aixinjueluo ◽  
Si-Yao Li ◽  
Lisa-L Song ◽  
Chung-Tai Lau ◽  
...  
Keyword(s):  
Systematic Reviews ◽  
Meta Analysis ◽  
Herbal Medicines ◽  
Reporting Quality ◽  
Primary Analysis ◽  
Chinese Herbal Medicines ◽  
Chinese Herbal ◽  
Related Information ◽  
Meta Analyses

Abstract Background Chinese herbal medicines (CHMs) are the major interventions of traditional Chinese medicine (TCM), which are typically administered as either single herbs or formulas. The Cochrane systematic reviews (SRs) of CHMs are essential references for evaluating the efficacy and safety of CHMs interventions; they are expected to be accurate and reliable. This study aimed to assess the reporting quality of these SRs, particularly whether necessary information related to CHM was adequately reported. Methods The Cochrane Database was systematically searched for all SRs of CHM that were published up to 31 December 2017. The primary analysis was to assess their reporting quality based on 27-item of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) and 9-item of CHM-related information designed according to TCM theory. Descriptive statistics were additionally used to analyze their baseline characteristics. Results A total of 109 Cochrane SRs of CHM were identified from 1999 to 2017. For 27-item of PRISMA, 26 had the reporting compliances higher than 50%, of which 11 were fully reporting (100%). However, for CHM-related information, 65 (59.6%) SRs did not report the specific name of the CHM in the title, 42 (38.5%) lacked TCM-related rationales in the introduction, 62 (56.9%) did not include CHM-related characteristics in the additional analyses, and 77 (70.6%) did not analyze CHM results in terms of TCM-related theories in the discussion. Of 97 SRs that included clinical trials, 38 (39.2%) did not provide the details of composition and dosage of CHMs, 85 (87.6%) did not report the CHM sources, 13 (13.4%) did not provide the dosage form, 95 (97.9%) lacked CHM quality control information, and 57 (58.8%) did not describe details of the controls. For 62 (72.9%) of 85 SRs that included meta-analysis, it was impossible to assess whether meta-analysis had been properly conducted due to inadequate reporting of CHM interventions. Conclusion Although the Cochrane SRs of CHM showed reporting compliance with PRISMA checklist, their reporting quality needs improvement, especially about full reporting of CHM interventions and of TCM-related rationales. Reporting guideline of “PRISMA extension for CHM interventions” should be developed thus to improve their quality.

Sign in / Sign up

Export Citation Format

Share Document